{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:25:16Z","timestamp":1787009116654,"version":"build-2736575974"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:00:00Z","timestamp":1697241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Japanese men receiving apalutamide often experience skin-adverse events (AEs), possibly requiring treatment interruption or dose reduction. However, concerns have arisen regarding the impact of these adjustments on the efficacy of apalutamide. Our study evaluated the efficacy, safety, and persistence of apalutamide in men with metastatic castration-sensitive prostate cancer (mCSPC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed the medical records of 108 men with mCSPC from 14 Japanese institutions. The primary outcomes were the efficacy of apalutamide: prostate-specific antigen (PSA) response (50%, 90% and\u00a0&amp;lt;\u00a00.2 decline) and progression to castration-resistant prostate cancer (CRPC). The secondary outcomes were the skin-AE and compliance of apalutamide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PSA50%, PSA90% and PSA\u00a0&amp;lt;\u00a00.2 declines were observed in 89.8, 84.3 and 65.7%, and the median time to CRPC progression was not reached. PSA\u00a0&amp;lt;\u00a00.2 decline and an initial full dose of apalutamide were significantly associated with a longer time to CRPC. The most common AE was skin-AE (50.9%), and there was no association between the occurrence of skin-AE and the time to CRPC (P\u00a0=\u00a00.72). The median apalutamide persistence was 29\u00a0months, which was longer in the initial full dose recipients than in the reduced dose recipients. The dosage is reduced in about 60% of patients within the first year of treatment in the initial full dose recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings indicate the effectiveness of apalutamide in Japanese men with mCSPC, despite a substantial portion requiring dose reduction within a year among the initial full dose recipients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyad143","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T11:59:34Z","timestamp":1695902374000},"page":"167-174","source":"Crossref","is-referenced-by-count":14,"title":["Real-world prostate-specific antigen response and progression to castration-resistant prostate cancer among men with metastatic castration-sensitive prostate cancer treated with apalutamide: a multi-institutional study in the Chu-shikoku Japan Urological Consortium"],"prefix":"10.1093","volume":"54","author":[{"given":"Yoichiro","family":"Tohi","sequence":"first","affiliation":[{"name":"Kagawa University Department of Urology, Faculty of Medicine, , Kita-gun, Kagawa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Kato","sequence":"additional","affiliation":[{"name":"Kagawa University Department of Urology, Faculty of Medicine, , Kita-gun, Kagawa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Yamaguchi University Department of Urology, Graduate School of Medicine, , Yamaguchi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Daizumoto","sequence":"additional","affiliation":[{"name":"Tokushima University Graduate School of Biomedical Sciences Department of Urology, , Tokushima"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"Kochi Medical School Department of Urology, , Nankoku, Kochi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Ohira","sequence":"additional","affiliation":[{"name":"Kawasaki Medical School Department of Urology, , Okayama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Katayama","sequence":"additional","affiliation":[{"name":"Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Department of Urology, , Okayama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryutaro","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Tottori University Faculty of Medicine Division of Urology, Department of Surgery, , Tottori"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takamoto","sequence":"additional","affiliation":[{"name":"Fukuyama City Hospital Department of Urology, , Hiroshima"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Ehime University Department of Urology, , Toon, Ehime"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Hiroshima University Department of Urology, Graduate School of Biomedical and Health Sciences, , Hiroshima"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Nagami","sequence":"additional","affiliation":[{"name":"Shimane University, Faculty of Medicine Department of Urology, , Izumo, Shimane"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Hayashida","sequence":"additional","affiliation":[{"name":"Sakaide City Hospital Department of Urology, , Sakaide, Kagawa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Hirama","sequence":"additional","affiliation":[{"name":"KKR Takamatsu Hospital Department of Urology, , Takamatsu, Kagawa , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Naito","sequence":"additional","affiliation":[{"name":"Kagawa University Department of Urology, Faculty of Medicine, , Kita-gun, Kagawa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Tomida","sequence":"additional","affiliation":[{"name":"Tokushima University Graduate School of Biomedical Sciences Department of Urology, , Tokushima"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Tokushima University Graduate School of Biomedical Sciences Department of Urology, , Tokushima"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinkuro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Kochi Medical School Department of Urology, , Nankoku, Kochi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinjiro","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Kawasaki Medical School Department of Urology, , Okayama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikio","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Kagawa University Department of Urology, Faculty of Medicine, , Kita-gun, Kagawa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Chu-shikoku Japan Urological Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,14]]},"reference":[{"key":"2024020717395150200_ref1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"2024020717395150200_ref2","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"2024020717395150200_ref3","volume-title":"National Comprehensive Cancer Network Clinical practice guidelines in oncology prostate cancer version 1","year":"2023"},{"key":"2024020717395150200_ref4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO- ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"key":"2024020717395150200_ref5","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/iju.14993","article-title":"Treatment strategies and outcomes in a long-term registry study of patients with high-risk metastatic hormone-na\u00efve prostate cancer in Japan: an interim analysis of the J-ROCK study","volume":"29","author":"Uemura","year":"2022","journal-title":"Int J Urol"},{"key":"2024020717395150200_ref6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12894-020-00689-0","article-title":"Skin rash following administration of apalutamide in Japanese patients with advanced prostate cancer: an integrated analysis of the phase 3 Spartan and Titan studies and a phase 1 open-label study","volume":"20","author":"Uemura","year":"2020","journal-title":"BMC Urol"},{"key":"2024020717395150200_ref7","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/iju.14843","article-title":"Safety and efficacy of apalutamide in Japanese patients with metastatic castration- sensitive prostate cancer receiving androgen deprivation therapy: final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study","volume":"29","author":"Uemura","year":"2022","journal-title":"Int J Urol"},{"key":"2024020717395150200_ref8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/pros.24453","article-title":"Effects of apalutamide dose reduction on skin-related adverse events in patients with advanced prostate cancer: a multicenter retrospective study","volume":"83","author":"Oishi","year":"2023","journal-title":"Prostate"},{"key":"2024020717395150200_ref9","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.21873\/anticanres.15682","article-title":"Low body weight as a risk factor for apalutamide-related cutaneous adverse events","volume":"42","author":"Katsuta","year":"2022","journal-title":"Anticancer Res"},{"key":"2024020717395150200_ref10","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1007\/s10147-022-02183-z","article-title":"Chu-shikoku Japan urological consortium. Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan urological consortium","volume":"27","author":"Tohi","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"2024020717395150200_ref11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12894-023-01246-1","article-title":"A retrospective study on the incidence, management and risk factors of skin rash in patients with advanced prostate cancer in Japan","volume":"23","author":"De Moor","year":"2023","journal-title":"BMC Urol"},{"key":"2024020717395150200_ref12","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1158\/1078-0432.CCR-20-1041","article-title":"Efficacy and safety exposure\u2013response relationships of apalutamide in patients with non-metastatic castration-resistant prostate cancer","volume":"26","author":"Perez-Ruixo","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2024020717395150200_ref13","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"2024020717395150200_ref14","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Prostate cancer clinical trials working group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"2024020717395150200_ref15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","article-title":"Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer","volume":"34","author":"Chowdhury","year":"2023","journal-title":"Ann Onco"},{"key":"2024020717395150200_ref16","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","article-title":"STAMPEDE investigators. Abiraterone in ``high-'' and ``low-risk'' metastatic hormone-sensitive prostate cancer","volume":"76","author":"Hoyle","year":"2019","journal-title":"Eur Urol"},{"key":"2024020717395150200_ref17","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2017.75.3921","article-title":"ECOG-ACRIN 3805 investigators. Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel","volume":"36","author":"Harshman","year":"2018","journal-title":"J Clin Oncol"},{"key":"2024020717395150200_ref18","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1200\/JCO.2006.06.4246","article-title":"Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from southwest oncology group trial 9346 (INT-0162)","volume":"24","author":"Hussain","year":"2006","journal-title":"J Clin Oncol"},{"key":"2024020717395150200_ref19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4103\/aja.aja_64_21","article-title":"Apalutamide for patients with metastatic castration-sensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial","volume":"24","author":"Chung","year":"2022","journal-title":"Asian J Androl"},{"key":"2024020717395150200_ref20","doi-asserted-by":"crossref","first-page":"e0258160","DOI":"10.1371\/journal.pone.0258160","article-title":"Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer","volume":"16","author":"Tsuzuki","year":"2021","journal-title":"PloS One"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/2\/167\/56610740\/hyad143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/2\/167\/56610740\/hyad143.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T12:55:59Z","timestamp":1707310559000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/54\/2\/167\/7317598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,14]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,10,14]]},"published-print":{"date-parts":[[2024,2,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyad143","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,10,14]]}}}